T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control

Authors:

Abstract
Antigen-specific CD8+ T cell accumulation in tumors is a prerequisite for effective immunotherapy, and yet the mechanisms of lymphocyte transit are not well defined. Here we show that tumor-associated lymphatic vessels control T cell exit from tumors via the chemokine CXCL12, and intratumoral antigen encounter tunes CXCR4 expression by effector CD8+ T cells. Only high-affinity antigen downregulates CXCR4 and upregulates the CXCL12 decoy receptor, ACKR3, thereby reducing CXCL12 sensitivity and promoting T cell retention. A diverse repertoire of functional tumor-specific CD8+ T cells, therefore, exit the tumor, which limits the pool of CD8+ T cells available to exert tumor control. CXCR4 inhibition or loss of lymphatic-specific CXCL12 boosts T cell retention and enhances tumor control. These data indicate that strategies to limit T cell egress might be an approach to boost the quantity and quality of intratumoral T cells and thereby response to immunotherapy.
Funding Information
  • U.S. Department of Health &Human Services | National Institutes of Health (P30-CA069533, P30CA016087, R01CA238163, T32CA106195, T32GM136542, F31CA268726-01A1, P30-CA069533, R56 AR078686, R01 AR080436)
  • Cancer Research Institute
  • Melanoma Research Alliance (403191)
  • American Cancer Society (RSG-18-169-01-LIB)
  • Vetenskapsrådet (2016-00215)
  • American Association for Cancer Research (SU2C-AACR-DT14-14)
  • Brenden-Colson Center for Pancreatic Health

This publication has 70 references indexed in Scilit: